ID Biomedical To Initiate Fluviral Trial For U.S. Approval By End Of January
This article was originally published in The Pink Sheet Daily
Executive Summary
ID Biomedical will begin enrolling subjects in a clinical trial evaluating its influenza vaccine Fluviral for U.S. approval before the end of January
You may also be interested in...
FDA Accepts ID Biomedical’s Fluviral For Accelerated Approval Pathway
Accelerated approval could allow the company to market the influenza vaccine in the U.S. in time for the 2006-2007 flu season, the company says. ID Biomedical previously discussed the possibility of launching in 2005.
FDA Accepts ID Biomedical’s Fluviral For Accelerated Approval Pathway
Accelerated approval could allow the company to market the influenza vaccine in the U.S. in time for the 2006-2007 flu season, the company says. ID Biomedical previously discussed the possibility of launching in 2005.
FDA Using “Dual-Track” Plan To Strengthen 2005-2006 Flu Vaccine Supply
The agency will inspect Chiron’s Liverpool manufacturing facility in the spring to determine whether the company has “adequately addressed its problems,” CBER Director Goodman tells House committee. FDA informs manufacturers that it will allow accelerated approval of flu vaccines using surrogate endpoints.